埃及奥密克戎暴发前不同类型疫苗对SARS-CoV-2最常见变异株诱导的体液免疫
本研究在埃及采集已接种疫苗参与者的血清,用微量中和试验检测针对SARS-CoV-2变异株的中和活性。结果显示,BNT162b2(辉瑞-BioNTech)、ChAdOx1 nCov-19(阿斯利康)和Ad26.COV2.S(杨森)疫苗针对B.1、C.36.3和AY.32(德尔塔)变异株诱导的中和抗体反应强于BBIBP-CorV疫苗(国药)。作者指出疫苗仍高效,但需持续监测疫苗有效性。
要点
- BNT162b2、ChAdOx1 nCov-19和Ad26.COV2.S疫苗针对B.1、C.36.3和AY.32变异株的中和抗体反应强于BBIBP-CorV疫苗。
- 研究采用微量中和试验检测接种者血清对SARS-CoV-2变异株的中和活性。
- 作者认为需持续监测疫苗有效性。
核心结论
- BNT162b2、ChAdOx1 nCov-19和Ad26.COV2.S疫苗针对B.1、C.36.3和AY.32(德尔塔)变异株诱导的中和抗体反应强于BBIBP-CorV疫苗。
- 疫苗在管理COVID-19大流行中仍高度有效,但需持续监测疫苗有效性。
研究设计与样本
- 研究采集已接种疫苗参与者的血清样本,采用微量中和试验检测针对SARS-CoV-2变异株的中和活性。
主要发现
- BNT162b2(辉瑞-BioNTech)、ChAdOx1 nCov-19(阿斯利康)和Ad26.COV2.S(杨森)疫苗针对B.1、C.36.3和AY.32(德尔塔)变异株诱导的中和抗体反应强于BBIBP-CorV疫苗(国药)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.
引用
- El-Shesheny R, El Taweel A, Gomaa MR, et al. Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak. Vaccine. 2022. PMID: 35697574. doi:10.1016/j.vaccine.2022.05.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。